Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05388435 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
A Phase 1 study, sponsored by SK Life Science.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05388435 is a Phase 1 study that was terminated before completion, run by SK Life Science. The registered enrollment target is 15 participants.
The verdict
NCT05388435, a Phase 1 study, was terminated before completion, sponsored by SK Life Science.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Primary Objective of Part 1 (Dose Escalation Phase): Evaluate the safety and tolerability of SKL27969, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of SKL27969 Primary Objective of Part 2 (Dose Expansion Phase): Evaluate the preliminary anti-tumor activity of SKL27969
Interventions
- DRUG SKL27969
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05388435
The ClinicalTrials.gov registry entry for NCT05388435 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SKL27969 is the first listed.
NCT05388435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05388435 about?
NCT05388435 is a clinical study titled "Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients". Primary Objective of Part 1 (Dose Escalation Phase): Evaluate the safety and tolerability of SKL27969, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of SKL27969 Primary Objective of Part 2 (Dose Expansion Phase): Evaluate the preliminary anti-tumor activity o...
What is the current status of trial NCT05388435?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-09-12. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT05388435?
The interventions under investigation include: SKL27969 (DRUG).
Who is sponsoring clinical trial NCT05388435?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.